Case Reports:

This article has an addendum. Addendum in: Oncotarget. 2022; 13:982-982.

A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Sewanti Limaye _, Prashant Kumar _, Ramya Pragya, Janani Sambath, Darshana Patil, Ajay Srinivasan, Sachin Apurva, Navin Srivastava, Sanket Patil, Revati Patil, Vineet Datta, Dadasaheb Akolkar and Rajan Datar

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2020; 11:4358-4363. https://doi.org/10.18632/oncotarget.27809

Metrics: PDF 925 views  |   Full Text 2547 views  |   ?  


Sewanti Limaye1, Prashant Kumar2,3,4, Ramya Pragya1, Janani Sambath3,4, Darshana Patil2, Ajay Srinivasan2, Sachin Apurva2, Navin Srivastava2, Sanket Patil2, Revati Patil2, Vineet Datta2, Dadasaheb Akolkar2 and Rajan Datar2

1 Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India

2 Datar Cancer Genetics Limited, Nasik, Maharashtra, India

3 Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India

4 Manipal Academy of Higher Education, Manipal, Karnataka, India

Correspondence to:

Sewanti Limaye,email: [email protected]
Prashant Kumar,email: [email protected]

Keywords: high grade serous ovarian cancer; androgen receptors; bicalutamide

Received: July 16, 2020     Accepted: October 27, 2020     Published: November 17, 2020

Copyright: © 2020 Limaye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Ovarian cancer is common gynaecological malignancy and a leading cause of death among women. Despite the advances in treatment strategies, majority of patients present with recurrence after first- or second-line treatment. Targeted therapy that has proven to be effective in other advanced or metastatic solid tumors have also demonstrated its efficacy in ovarian cancer. Recent studies have shown that the androgen receptor (AR) signalling is involved in pathogenicity and progression of cancer. Current observations suggest AR could be a potential target in managing the disease. In this case report we present a patient with high grade serous ovarian cancer (HGSOC) with multiple relapses with excellent disease control on AR inhibition with bicalutamide.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27809